Evidence map›Paper›PMID 29524830›Full record

ArticleTranslational oncology2018

Tumstatin, a Matrikine Derived from Collagen Type IVα3, is Elevated in Serum from Patients with Non-Small Cell Lung Cancer.

Signe Holm Nielsen, Nicholas Willumsen, Susanne Brix, Shu Sun, Tina Manon-Jensen, Morten Karsdal, Federica Genovese

Open access · goldAbstract read
In one paragraph

Article in Translational oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.4field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 31 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Observational
  12. Review
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Signe Holm NielsenFibrosis Biology and Biomarkers, Nordic Bioscience A/S, Herlev, Denmark; Disease Systems Immunology, Department of Biotechnology and Biomedicine, Technical University of Denmark, Lyngby, Denmark. Electronic address: shn@nordicbio.com.
Nicholas WillumsenFibrosis Biology and Biomarkers, Nordic Bioscience A/S, Herlev, Denmark.
Susanne BrixDisease Systems Immunology, Department of Biotechnology and Biomedicine, Technical University of Denmark, Lyngby, Denmark.
Shu SunFibrosis Biology and Biomarkers, Nordic Bioscience A/S, Herlev, Denmark.
Tina Manon-JensenFibrosis Biology and Biomarkers, Nordic Bioscience A/S, Herlev, Denmark.
Morten KarsdalFibrosis Biology and Biomarkers, Nordic Bioscience A/S, Herlev, Denmark.
Federica GenoveseFibrosis Biology and Biomarkers, Nordic Bioscience A/S, Herlev, Denmark.
Nordic Bioscience (Denmark) · DKTechnical University of Denmark · DK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID29524830
PMCPMC5884192
OpenAlexW2793028490

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.